Denibulin can be used as a vascular disrupting agent or vascular occlusion agent, specifically as the dihydrochloride salt of methyl N-[5-[[4-[[(2S)-2-amino-1-oxopropyl]amino]phenyl]thio]-1H-benzimidazol-2-yl]carbamate (MN-029·2HCl). It is applicable in the treatment of various diseases driven by angiogenesis-induced neovascularization, such as cancer, psoriasis, rheumatoid arthritis, macular degeneration, and atherosclerotic plaques. In oncology, for example, tumor growth relies on the formation of new blood vessels to supply essential nutrients and oxygen to the growing tumor. The newly formed vasculature also serves as a conduit for removing toxic metabolic byproducts and chemotherapeutic agents from the vicinity of the tumor. Therefore, compounds that disrupt or inhibit neovascularization can be employed in the treatment of the aforementioned diseases. Denibulin is a known vascular disrupting agent and is currently being evaluated as a candidate therapeutic agent for cancer treatment.